Epidemiology of hospitalized strongyloidiasis in Japan: A nationwide administrative database study
9 affiliations
- 1Department of Respiratory Medicine, Wakamatsu Hospital of the University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
- 2Department of Environmental Epidemiology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
- 3Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
- 4Division of Infection Control and Prevention, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
- 5Department of Environmental Health Engineering, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
- 6Department of Preventive Medicine and Community Health, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
- 7Department of Nursing, Fukuoka International University of Health and Welfare, Fukuoka, Japan
- 8Department of Health Policy and Informatics, Institute of Science Tokyo, Tokyo, Japan
- 9Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Abstract
Strongyloidiasis remains endemic in parts of Japan, particularly Okinawa Prefecture, and can progress to disseminated disease with high mortality; however, nationwide data on hospitalized patients, including regional differences and the impact of disseminated disease, are limited. We conducted a retrospective nationwide study using the Diagnosis Procedure Combination database to identify hospitalized patients with strongyloidiasis in Japan between fiscal years 2014 and 2020, using ICD-10 code B78, with disseminated cases defined as B78.7. Demographic characteristics, geographic distribution, and outcomes were analyzed, with a focus on disseminated disease and regional differences between Okinawa and other areas. After excluding duplicate cases, 252 hospitalized patients were included (mean age, 77.6 years; male-to-female ratio, 1.47). Most patients were from the Kyushu and Okinawa regions, with Okinawa accounting for 82.1% of cases. Disseminated strongyloidiasis was identified in 44 patients (17.5%) and was associated with poorer neurological status at admission and higher in-hospital mortality; 11 patients with disseminated disease died during hospitalization (25.0%). Severe complications, including sepsis (54.5%) and meningitis (25.0%), were frequently observed in disseminated cases. Patients hospitalized outside Okinawa were younger than those hospitalized in Okinawa, whereas the proportions of disseminated disease and in-hospital mortality did not differ significantly between regions. In Japan, hospitalized patients diagnosed with strongyloidiasis were predominantly concentrated in Okinawa; however, severe cases also occurred in other regions. These findings highlight the importance of considering strongyloidiasis in patients with relevant epidemiological backgrounds, particularly in the setting of immunosuppression, regardless of their current geographic location.
Related
- Involving Patients in Pharmacoepidemiology Studies Conducted on Healthcare Administrative Database: Results of a Feasibility Study in France
- Evidence for patterns of colonization risk in the nationwide hospitalized patient network in France
- Glucocorticoid in giant cell arteritis: real-world treatment patterns over time and associated burden in a nationwide hospital-based study within the French health insurance database
- Win ratio analysis of surgical approaches for lung cancer: a nationwide observational study using the French national hospital discharge database
- The SARS-CoV-2 Integrated Genomic Epidemiology Database (IGED): Linking viral genomes with patient-level metadata to advance statewide genomic surveillance in California
BibTeX
@article{torii2026epidemiology,
title = {{Epidemiology of hospitalized strongyloidiasis in Japan: A nationwide administrative database study}},
author = {Ryo Torii and Naoaki Ohkubo and Kei Yamasaki and Masahiro Tahara and Kei Nakamura and Kentaro Akata and Hiroaki Ikegami and Chinatsu Nishida and Makoto Okawara and Yoshihisa Fujino and Shinya Matsuda and Kiyohide Fushimi and Hiroshi Mukae and Kazuhiro Yatera},
journal = {Parasite Epidemiology and Control},
year = {2026},
month = oct,
doi = {10.1016/j.parepi.2026.e00555},
url = {https://doi.org/10.1016/j.parepi.2026.e00555},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Epidemiology of hospitalized strongyloidiasis in Japan: A nationwide administrative database study
AU - Ryo Torii
AU - Naoaki Ohkubo
AU - Kei Yamasaki
AU - Masahiro Tahara
AU - Kei Nakamura
AU - Kentaro Akata
AU - Hiroaki Ikegami
AU - Chinatsu Nishida
AU - Makoto Okawara
AU - Yoshihisa Fujino
AU - Shinya Matsuda
AU - Kiyohide Fushimi
AU - Hiroshi Mukae
AU - Kazuhiro Yatera
PY - 2026
DA - 2026/10/10
JO - Parasite Epidemiology and Control
DO - 10.1016/j.parepi.2026.e00555
UR - https://doi.org/10.1016/j.parepi.2026.e00555
AB - Strongyloidiasis remains endemic in parts of Japan, particularly Okinawa Prefecture, and can progress to disseminated disease with high mortality; however, nationwide data on hospitalized patients, including regional differences and the impact of disseminated disease, are limited. We conducted a retrospective nationwide study using the Diagnosis Procedure Combination database to identify hospitalized patients with strongyloidiasis in Japan between fiscal years 2014 and 2020, using ICD-10 code B78, with disseminated cases defined as B78.7. Demographic characteristics, geographic distribution, and outcomes were analyzed, with a focus on disseminated disease and regional differences between Okinawa and other areas. After excluding duplicate cases, 252 hospitalized patients were included (mean age, 77.6 years; male-to-female ratio, 1.47). Most patients were from the Kyushu and Okinawa regions, with Okinawa accounting for 82.1% of cases. Disseminated strongyloidiasis was identified in 44 patients (17.5%) and was associated with poorer neurological status at admission and higher in-hospital mortality; 11 patients with disseminated disease died during hospitalization (25.0%). Severe complications, including sepsis (54.5%) and meningitis (25.0%), were frequently observed in disseminated cases. Patients hospitalized outside Okinawa were younger than those hospitalized in Okinawa, whereas the proportions of disseminated disease and in-hospital mortality did not differ significantly between regions. In Japan, hospitalized patients diagnosed with strongyloidiasis were predominantly concentrated in Okinawa; however, severe cases also occurred in other regions. These findings highlight the importance of considering strongyloidiasis in patients with relevant epidemiological backgrounds, particularly in the setting of immunosuppression, regardless of their current geographic location.
SN - 2405-6731
ER -